Uncategorized Archives - Page 241 of 248

ThursdayMar 16, 2017 1:15 pm

InMed Pharmaceuticals (IMLFF) Lead Product Candidate Targeting Rare, Incurable Skin Disease

With a prevalence of 20 per million newborns in the United States, and an estimated 500,000 patients worldwide, epidermolysis bullosa is a group of rare inherited skin diseases that range in severity from mild to lethal and have no currently approved or known cure or treatment. The condition was brought to the public attention in the early 2000s, and, since then, efforts to find a cure have not born fruit, with most research and development focusing instead on addressing the symptoms, such as reducing blistering and swelling and preventing wounds and pain. However, a new product currently in development by…

ThursdayMar 16, 2017 8:30 am

Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (ZYNE), OWC Pharmaceutical Research Corp. (OWCP), Insys Therapeutics, Inc. (INSY) and GW Pharmaceuticals plc (GWPH) are carving lanes of unprecedented opportunities in the…

WednesdayMar 15, 2017 8:30 am

“No-Touch” Approach Reduces Risk as Public Companies Tap Explosive Growth of Cannabis Industry

The marijuana industry is the new investing frontier. As a result of last November’s elections, eight states and the District of Columbia now allow the recreational use of marijuana, while another 28 states permit its use for medicinal purposes. In what has been touted as the fastest-growing industry in the U.S., investment opportunities in the cannabis space appear boundless. Companies like Singlepoint, Inc. (SING) (SING Profile), American Cannabis Company Inc. (AMMJ), General Cannabis Corp. (CANN), The Scotts Miracle-Gro Company (SMG) and Terra Tech Corp. (TRTC) are all employing a “no-touch” approach to their cannabis business models. By creating business models…

WednesdayMar 15, 2017 8:30 am

Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn’t appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), GW Pharmaceuticals plc (GWPH), Zynerba Pharmaceuticals, Inc. (ZYNE), AXIM® Biotechnologies, Inc. (AXIM) and…

TuesdayMar 14, 2017 10:41 am

India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its…

FridayMar 10, 2017 3:22 pm

The Diversified Domain of Easton Pharmaceuticals, Inc. (EAPH)

Drug development. Medical marijuana. Female diagnostics and treatments. These high-growth industries and sectors are the focal points of Easton Pharmaceuticals, Inc.’s (OTC: EAPH) operations. A diversified and specialty company based in Canada, Easton’s operation spans multiple pharmaceutical sectors and other emergent industries, including the medical marijuana market. In its day-to-day operations, the company balances three mission goals: It develops and acquires drugs, diagnostics and treatment products that build shareholder value. It delivers safe, effective and proven products that improve the health and well-being of men and women across global jurisdictions. It builds and capitalizes on fast-growing and promising industries and…

FridayMar 10, 2017 9:11 am

Singlepoint, Inc. (SING) Showing Growth through Its Strategic Acquisition Plan

Singlepoint, Inc. (OTC: SING), a publicly traded holding company based in Arizona, has been highlighted as one to look out for in the cannabis space, according to InsiderFinancial.com (http://nnw.fm/f5UrR). The company, through its SingleSeed subsidiary, provides business services to cannabis businesses, including marketing, point of sale and more. Because of the company’s nature, and its ability to fill a very challenging gap in the marijuana industry, Singlepoint is on a climb as the industry continues to flourish in the United States. This has been reflected in its stock price, which at the time of InsiderFinancial’s coverage had shown a 560%…

WednesdayMar 08, 2017 8:30 am

Strong Technical Interface Making Cannabis Industry More Profitable and Efficient

Any fast-growing business needs an operational framework to help it develop and better serve its customers, and the marijuana industry is no different. As the legal cannabis market continues its impressive expansion, a growing number of companies are emerging to form a legal support framework of related technology and ancillary services that are driving the industry toward an efficient and profitable structure. Companies such as SinglePoint, Inc. (SING) (SING Profile), MassRoots, Inc. (MSRT), mCig. Inc. (MCIG), Rocky Mountain High Brands, Inc. (RMHB) and Innovative Industrial Properties, Inc. (IIPR) are branching out into different segments of the industry, determined to make…

TuesdayMar 07, 2017 9:14 am

SeeThruEquity Issues Update on ChineseInvestors.com (CIIX), Increases Price Target to $3.75

Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75. The previous price target for CIIX, issued in October 2016, was $2.05. SeeThruEquity delivers unbiased and unpaid for equity research for publicly traded companies with market capitalizations of less than $1 billion. The increased target price reflects the added potential from legal cannabis initiatives taken by ChineseInvestors.com. Though in the early stages of penetrating the legal cannabis market, ChineseInvestors.com has demonstrated prior success with its profitable investment in Medicine Man Technologies, generating $2.3 million…

MondayMar 06, 2017 9:52 am

InMed Pharmaceuticals, Inc. (IMLFF) is “One to Watch”

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver. Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases,…